Opportunities for acquiring external assets may move faster than an internal BD group can react. Inova supports a capability to be both fast and nimble in the hunt for novel assets from scouting through to licensing and beyond to alliance management. Read more »
The quality of medical treatment is dependent on rapid and accurate diagnosing of the disease, as well as safeguarding the life of the patient. Apart from infectious diseases, most diseases do not have that “tell-all” diagnostic marker that provides an adequate picture of the patient and their particular disease. Seegene, Inc., sees a combination of surrogate markers in a single clinically validated assay as the most effective tool in disease identification, treatment and management, while keeping the patient in focus. Read more »
Kees Been, CEO of EnVivo, arrives in Milan for BIO-Europe Spring looking for partners who can help bring his lead CNS products to market. Read more »
Right now is the right moment to look closer at Repros Therapeutics, which holds two highly differentiated, highly protected products that each meets a growing demand in two very large markets, one for men’s health and the other for women’s health. Read more »
Newsletter